These concerns are even more important and urgent when companies of embolic agents provide us with questionable interpretations of study results. In the 2004 Matrix Newsletter, the results of the so-called ACTIVE Study are presented (2). Matrix coils are coated with a biologically active substance and proved to accelerate healing of intracranial aneurysms in swine, and it is concluded that these
. coils may prevent aneurysmal recanalization after endovascular treatment of cerebral aneurysms (3). The first page of the newsletter states, "The ACTIVE Study represents the first prospective multicenter trial designed to evaluate the benefit of the Matrix Detachable Coil for the treatment of cerebral aneurysms and was sponsored by Boston Scientific, Neurovascular, Fremont, CA."
